Recent Updates
Recently added Catalysts
ALT Positive Sentiment Score: 65/100

Altimmune to Participate at Two Upcoming Investor Conferences

Wednesday, August 30, 2023 1 min read
Key Takeaway: Altimmune, Inc. (Nasdaq: ALT) announced that its management team will attend two investor conferences: the Wells Fargo 2023 Healthcare Conference and the Morgan Stanley 21st Annual Global Healthcare Conference. These events will feature presentations and provide opportunities for one-on-one meetings. Altimmune is focused on developing innovative therapeutics for obesity and liver diseases, showcasing their lead product candidate, pemvidutide, among others. Webcast access for the sessions is available on the company's website, facilitating broader engagement.

Market Sentiment Analysis

POSITIVE FACTORS

  • Participation in multiple investor conferences indicates strong engagement with the investment community.
  • The opportunity for one-on-one meetings may generate interest in Altimmune's innovative therapeutics.
  • Highlighting promising product candidates such as pemvidutide and HepTcell™ shows potential for future growth.

Full Press Release Details

GAITHERSBURG, Md., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate and be available for 1x1 meetings at the following investor conferences:
Wells Fargo 2023 Healthcare Conference in Everett, MA
Wednesday, September 6, 2023
Fireside chat at 3:45 pm Eastern Time
Morgan Stanley 21st Annual Global Healthcare Conference in New York, NY
Wednesday, September 13, 2023
Fireside chat at 1:35 pm Eastern Time
The sessions will be webcast and can be accessed by visiting the Events section of the Altimmune website.
Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation therapeutics for the treatment of obesity and liver diseases. The Company’s lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell™, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter
Altimmune Investor & Media Contact:
Chief Financial Officer
reisenstadt@altimmune.com

Frequently Asked Questions

What investor conferences will Altimmune participate in?

Altimmune will attend the Wells Fargo 2023 Healthcare Conference and the Morgan Stanley 21st Annual Global Healthcare Conference.

When is Altimmune's fireside chat at the Wells Fargo Conference?

The fireside chat at the Wells Fargo Conference is on September 6, 2023, at 3:45 pm ET.

What is pemvidutide developed for?

Pemvidutide is a dual receptor agonist aimed at treating obesity and NASH.

What does HepTcell™ target?

HepTcell™ is designed to achieve a functional cure for chronic hepatitis B.

Where can I access Altimmune's conference webcasts?

You can access the webcasts in the Events section of Altimmune's website.

Tags: ALT Viatris Investor Conferences Healthcare Altimmune pemvidutide HepTcell investor conferences healthcare
Last updated: Aug 30, 2023